LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Akcijų sąrašas・Sana Biotechnology Inc

Sana Biotechnology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.15 1.61

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.01

Max

3.17

Pagrindiniai rodikliai
By Trading Economics
Pajamos	12M -47M
Pelnas, tenkantis vienai akcijai	-0.171
Darbuotojai	142
EBITDA	23M -35M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+179.1% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-115M 846M
Ankstesnė atidarymo kaina	1.54
Ankstesnė uždarymo kaina	3.15

Naujienos nuotaikos

By Acuity

25%

75%

48 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

1.68 / 1.87 Palaikymas ir pasipriešinimas

Sana Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-21 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Conduent to Sell Public Transit Business to Modaxo for $164 Million

2026-05-21 16:49; UTC

Uždarbis

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

2026-05-21 16:26; UTC

Pagrindinės rinkos jėgos

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

2026-05-21 23:51; UTC

Rinkos pokalbiai

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

2026-05-21 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

2026-05-21 23:30; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-21 23:30; UTC

Rinkos pokalbiai

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

2026-05-21 22:33; UTC

Įsigijimai, susijungimai, perėmimai

Conduent to Sell Public Transit Business to Modaxo for $164M

2026-05-21 21:53; UTC

Uždarbis

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

2026-05-21 21:02; UTC

Uždarbis

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

2026-05-21 20:55; UTC

Uždarbis

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

2026-05-21 20:30; UTC

Karštos akcijos

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

2026-05-21 20:20; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-21 20:20; UTC

Rinkos pokalbiai

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

2026-05-21 20:20; UTC

Uždarbis

Webull 1Q Adj EPS 3c >BULL

2026-05-21 20:20; UTC

Uždarbis

Webull 1Q Rev $159.9M >BULL

2026-05-21 20:18; UTC

Rinkos pokalbiai

Mexico's Inflation Seen Easing in Early May -- Market Talk

2026-05-21 20:18; UTC

Uždarbis

Webull 1Q Loss/Shr 4c

2026-05-21 19:43; UTC

Rinkos pokalbiai

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

2026-05-21 19:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

2026-05-21 18:58; UTC

Uždarbis

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

2026-05-21 18:15; UTC

Rinkos pokalbiai

Gold Higher For Second Consecutive Day -- Market Talk

2026-05-21 17:40; UTC

Rinkos pokalbiai

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

2026-05-21 17:04; UTC

Rinkos pokalbiai

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

2026-05-21 17:01; UTC

Uždarbis

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

2026-05-21 16:20; UTC

Rinkos pokalbiai

Uždarbis

Stellantis Targets Distant but Constructive -- Market Talk

2026-05-21 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Sana Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

179.1% į viršų

12 mėnesių prognozė

Vidutinis 8.68 USD 179.1%

Aukščiausias 16 USD

Žemiausias 3.07 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sana Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Sana Biotechnology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.68 / 1.87Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Rinkos nuotaikos

By Acuity

48 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.